Andrew King
Company: Chinook Therapeutics
Job title: Chief Scientific Officer
Seminars:
Chair’s Opening Remarks 7:55 am
day: Day Two
Panel Discussion: Accelerated Approval, Small Patient Populations & Precision Medicine: Executing Clinical Trials in Rare Kidney Diseases 9:00 am
• Clarifying heterogeneous disease pathogenesis to investigate exciting targets • Analyzing the landscape for early and disease specific biomarkers to monitor disease progression • Navigating patient enrolment in the context of exploding competition for patients with specific disease criteriaRead more
day: Day Two
From Positive Proof of Concept to Phase III Registration Trial: Designing & Executing Robust Clinical Trials in Rare Disease Indications 8:00 am
• Accelerating development of BION-1301 for the treatment of IgAN • Exploring disease-modifying biomarkers assessments and optimizing trial design in rare disease populations • To orphan drug designation and beyond: enhancing clinical outcome in defined patient cohortsRead more
day: Day Two